Relmada Therapeutics Inc (RLMD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Relmada Therapeutics Inc (RLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11487
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treatment of neuropathic pain; REL-1028 BuTab, an oral tablet form of buprenorphine; REL-1015 LevoCap ER, an abuse resistant form of broad spectrum opioid levorphanol; and REL-1021 MepiGel, a topical gel dosage form of local anesthetic mepivacaine. It also develops analgesics and anti-arthritic medicines. The company offers products in the areas of chronic pain due to cancer, depression, ophthalmology, mitochondrial diseases, Rett syndrome, musculoskeletal disorders and peripheral neuropathy. Relmada Therapeutics is headquartered in New York, the US.

Relmada Therapeutics Inc (RLMD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Relmada Therapeutics Acquires Global Rights for Dextromethadone 10
Venture Financing 11
Camp Nine Raises USD11 Million in Venture Financing 11
Relmada Therapeutics Raises USD15 Million in Venture Financing 12
Relmada Therapeutics Raises US$8 Million In Series A Venture Financing 13
Relmada Raises US$0.2 Million In Venture Financing 14
Relmada Therapeutics Secures USD3 Million in Series A Funding Round 15
Equity Offering 16
Relmada Therapeutics Raises USD3.3 Million in Private Placement of Shares 16
Relmada Therapeutics Raises USD15.2 Million in Private Placement of Shares upon Exercise of Warrants 17
Camp Nine Raises USD2 Million in Private Placement of Shares 18
Debt Offering 19
Relmada Therapeutics to Raise USD6.8 Million in Private Placement of 7% Convertible Promissory Notes Due 2019 19
Acquisition 21
Camp Nine Acquires Relmada Therapeutics 21
Relmada Therapeutics Acquires Medeor 22
Relmada Therapeutics Inc – Key Competitors 23
Relmada Therapeutics Inc – Key Employees 24
Relmada Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Jun 28, 2017: Relmada Therapeutics appoints new chair of scientific advisory board 26
Jun 21, 2017: Relmada Therapeutics appoints new executive clinical advisor 27
Jun 15, 2017: Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors 28
Legal and Regulatory 29
May 18, 2017: Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company 29
Product News 30
01/24/2017: Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER 30
Other Significant Developments 31
Apr 16, 2018: BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Relmada Therapeutics Acquires Global Rights for Dextromethadone 10
Camp Nine Raises USD11 Million in Venture Financing 11
Relmada Therapeutics Raises USD15 Million in Venture Financing 12
Relmada Therapeutics Raises US$8 Million In Series A Venture Financing 13
Relmada Raises US$0.2 Million In Venture Financing 14
Relmada Therapeutics Secures USD3 Million in Series A Funding Round 15
Relmada Therapeutics Raises USD3.3 Million in Private Placement of Shares 16
Relmada Therapeutics Raises USD15.2 Million in Private Placement of Shares upon Exercise of Warrants 17
Camp Nine Raises USD2 Million in Private Placement of Shares 18
Relmada Therapeutics to Raise USD6.8 Million in Private Placement of 7% Convertible Promissory Notes Due 2019 19
Camp Nine Acquires Relmada Therapeutics 21
Relmada Therapeutics Acquires Medeor 22
Relmada Therapeutics Inc, Key Competitors 23
Relmada Therapeutics Inc, Key Employees 24
Relmada Therapeutics Inc, Subsidiaries 25

List of Figures
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Relmada Therapeutics Inc (RLMD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ARRIS International PLC:企業の戦略的SWOT分析
    ARRIS International PLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Valero Energy Corp (VLO):企業の財務・戦略的SWOT分析
    Valero Energy Corp (VLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Alamo Group, Inc.:企業の戦略・SWOT・財務分析
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Senhwa Biosciences Inc (6492)-製薬・医療分野:企業M&A・提携分析
    Summary Senhwa Biosciences Inc (Senhwa) is a drug development company that develops small molecule drugs for the treatment of cancer. The company’s products include CX-5461 and CX-4945. Its CX-5461 is a p53 activating Pol I inhibitor and anticancer compound for treating hematological malignancies. S …
  • Nuffield Health:企業の戦略的SWOT分析
    Nuffield Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Fujirebio Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Fujirebio Diagnostics Inc (FDI), a subsidiary of Fujirebio Inc is a healthcare diagnostic company that develops, manufactures and markets in-vitro diagnostic products and biomarker assays. The company’s products include manual kits, EIA kits, OEM custom solutions, multi-constituent controls, …
  • Curetis NV (CURE):企業の財務・戦略的SWOT分析
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • AxoGen Inc (AXGN):企業の財務・戦略的SWOT分析
    Summary AxoGen Inc (AxoGen) formerly LecTec Corp is a provider of surgical solutions to measure and monitor nerve functions. The company's products include AxoTouch two-point discriminator, AxoGuard nerve connector, Avance nerve graft, AcroVal NSTMS and AxoGuard nerve protector products, among other …
  • Futuren (FTRN)-エネルギー分野:企業M&A・提携分析
    Summary Futuren, formerly Theolia SA, is a wind energy producer that prospects, develops, constructs, installs and operates wind power projects. It specializes in designing and building onshore wind plants. Futuren conducts these operations for its own account as well as for third parties. The compa …
  • Danone SA:企業の戦略・SWOT・財務情報
    Danone SA - Strategy, SWOT and Corporate Finance Report Summary Danone SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Asseco Business Solutions SA (ABS):企業の財務・戦略的SWOT分析
    Asseco Business Solutions SA (ABS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Lohmann & Rauscher GmbH & Co. KG:企業の戦略的SWOT分析
    Lohmann & Rauscher GmbH & Co. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Copenhagen Infrastructure Partners KS:電力:M&Aディール及び事業提携情報
    Summary Copenhagen Infrastructure Partners KS (CIP) is a fund management service provider. The company provides structuring, executing and managing investments within energy infrastructure. It invests in energy infrastructure assets including offshore wind, onshore wind, offshore power transmission, …
  • J.B. Hunt Transport Services, Inc. (JBHT):企業の財務・戦略的SWOT分析
    J.B. Hunt Transport Services, Inc. (JBHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • FUJIFILM Holdings Corporation:企業の戦略・SWOT・財務分析
    FUJIFILM Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary FUJIFILM Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bulgarian Telecommunications Company (VIVACOM):企業の戦略的SWOT分析
    Bulgarian Telecommunications Company (VIVACOM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Comvita Ltd (CVT):企業の財務・戦略的SWOT分析
    Comvita Ltd (CVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Phoenix Global Resources Plc (PGR):石油・ガス:M&Aディール及び事業提携情報
    Summary Phoenix Global Resources Plc (Phoenix), formerly known as Andes Energia Plc, is an upstream oil and gas company. It conducts exploration, development and production of oil and gas for conventional and unconventional resources. It has diversified portfolio of oil and gas assets in Argentina. …
  • NEC Corporation:企業の戦略・SWOT・財務分析
    NEC Corporation - Strategy, SWOT and Corporate Finance Report Summary NEC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Qiagen NV (QIA):企業の財務・戦略的SWOT分析
    Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆